Sun Pharma On The Rising Path: Motilal Oswal 

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

Sun Pharmaceutical Industries Ltd. delivered higher-than-expected profitability on -

1. better traction in specialty portfolio/U.S. generics, and

b) extended benefit of lower opex.

Marketing efforts for the specialty portfolio remain constrained due to Covid-19, offering scope to gain further prescription share going forward.

We remain positive due to -

1. superior execution in the specialty portfolio,
2. strong abbreviated new drug application pipeline, and
3. outperformance in the branded generics segment.

Click on the attachment to read the full report:

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.